Published on 15 Aug 2022 on Zacks via Yahoo Finance

Glaukos (GKOS) Strong Portfolio Driving Sales Amid Competition

Article preview image

Glaukos Corporation GKOS is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. The strength in the iStent product line and solid execution across its global glaucoma and Corneal Health franchises augur well. The sustained recovery trends across segments and solid business prospects in spite of the pandemic-induced uncertainties raise optimism. Recent strategic alliances instill confidence in the stock.

The company is also engaged in boosting its portfolio through the development of new products. The company currently has 13 publicly-disclosed programs and another 10 yet-to-be-disclosed development programs underway. A number of these pipeline programs are in active pivotal clinical trials, including iStent infinite and iDose TR.

However, stiff competition in the medical device industry and vendor uncertainty are other headwinds. Meanwhile, a stringent regulatory approval process for the iDose platform and products is a woe.

NYSE.GKOS price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio

Glaukos Corporation GKOS is well-poised for growth in the coming quarters, courtesy of its favora...

Zacks via Yahoo Finance 28 Dec 2022

Glaukos (GKOS) Up 0.8% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for Glaukos (GKOS). Shares have added about 0....

Zacks via Yahoo Finance 2 Dec 2022

Despite currently being unprofitable, Glaukos (NYSE:GKOS) has delivered a 79% return to shareholders...

Glaukos Corporation (NYSE:GKOS) shareholders have seen the share price descend 16% over the month...

Simply Wall St. via Yahoo Finance 26 Nov 2022

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

Glaukos Corporation GKOS is well-poised for growth, backed by favorable clinical trial results an...

Zacks via Yahoo Finance 23 Nov 2022

Glaukos (GKOS) Beats on Q3 Earnings, Tightens Sales View

Glaukos Corporation GKOS reported an adjusted loss per share of 45 cents for the third quarter of...

Zacks via Yahoo Finance 3 Nov 2022

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates

Glaukos (GKOS) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estim...

Zacks via Yahoo Finance 2 Nov 2022

The Zacks Analyst Blog Highlights Nevro, Masimo, Abiomed and Glaukos

For Immediate Release Chicago, IL – October 28, 2022 – announces the list of stocks fea...

Zacks via Yahoo Finance 28 Oct 2022

Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Wall Street expects a year-over-year decline in earnings on lower revenues when Glaukos (GKOS) re...

Zacks via Yahoo Finance 26 Oct 2022

Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday By Benzinga

Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday 8 Sep 2022

Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR

Glaukos Corporation GKOS announced positive top-line data from two pivotal studies evaluating its...

Zacks via Yahoo Finance 8 Sep 2022